ЭНДОТЕЛИЙЗАВИСИМАЯ ВАЗОДИЛАТАЦИЯ И УРОВНИ ФОЛИЕВОЙ КИСЛОТЫ И ГОМОЦИСТЕИНА У БОЛЬНЫХ ПОДАГРОЙ
Аннотация
Проведено определение параметров вазомоторной функции эндотелия, уровня гомоцистеина, мочевой кислоты и фолиевой кислоты у больных подагрой. У больных подагрой выявлено нарушение эндотелийзависимой вазо- дилатации. В сравнении с контрольной группой (40,58±2,8%), у больных подагрой выявлено достоверно значительное уменьшение максимальной объемной скорости кровенаполнения (11,3±1,65%) (p<0,001). При изучении биохимических показателей в плазме крови выявлено по сравнению с контрольной группой (8,99±1,2 мкмоль/л), достоверное увеличение уровня гомоцистеина у больных подагрой (15,78±1,5) (p<0,001). Содержание фолиевой кислоты у больных подагрой (6,15±0,27 мкмоль/л) было достоверно ниже, чем в контрольной группе (19,3±3,8) (p<0,001). Нарушение эндотелийзависимой вазодилатации, повышение уровня гомоцистеина и сниженный уровень фолатов в плазме крови является неблагоприятным фактором возникновения сердечно-сосудистых заболеваний.
Литература
Ильиных, Е. В. Факторы риска развития кардиоваскулярных заболеваний у больных подагрой: автореф. дис. канд. мед. наук: 14.00.39/Е. В. Ильиных; Рос. мед. ун-т. -М., 2006. -21 с.
Полонецкий, Л.З. Исследование вазомоторной функции эндотелия плечевой артерии с использованием импедансной технологии у больных атеросклерозом./Л.З. Полонецкий [et al.]//Медицинская панорама. -2005. -№ 7. -С. 40-43.
Abbott, R. D. Gout and coronary heart disease: the Framingham Study./R.D. Abbott [et al.]//J Clin Epidemiol. -1988. -Vol. 41(3) -P. 237-242.
Austin, R.C. Role of hyperhomocysteinemia in endothelial dysfunction and atherotrombotic disease./R.C. Austin, S.R. Lentz, G.H. Werstuck//Cell Death Differ. -2004. -Vol.11. -P. 56-64.
Baldus, S. Oxypurinol improves coronary and peripheral endothelial function in patients with coronary artery disease./S. Baldus [et al.]//Free Radic Biol Med. -2005. -Vol. 39(9) -P. 1184-1190.
Berry, C. E. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications./C. E. Berry, J. M. Hare//J Physiol -2004. -Vol. 555(3) -P. 589-606.
Boogaerts, M.A. Mechanisms of vascular damage in gout and oxalosis: crystal induced, granulocyte mediated, endothelial injury./M.A. Boogaerts, D.E. Hammerschmidt//Thromb Haemost. -1983. -Vol. 50 -P. 576-580.
Cappola, T.P. Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy./T. P. Cappola [et al.]//Circulation -2001. -Vol.104 -P. 2407-2411.
Cardillo, C. Xanthine Oxidase Inhibition With Oxypurinol Improves Endothelial Vasodilator Function in Hypercholesterolemic but Not in Hypertensive Patients./C. Cardillo [et al.]//Hypertension 1997. -Vol. 30(1) -P. 57-63.
Cheng, T.T. Elevated serum homocysteine levels for gouty patients./T.T. Cheng [et al.]//Clin. Rheumatol. -2005. -Vol. 24(2). -P. 103-106.
Coull, B.M. Elevated plasma homocyst(e)ine concentration as a possible independent risk factor for Stroke./B. M. Coull [et al.]//Stroke -1990. -Vol. 21 -P. 572-576.
Doehner, W. Effects of Xanthine Oxidase Inhibition With Allopurinol on Endothelial Function and Peripheral Blood Flow in Hyperuricemic Patients With Chronic Heart Failure./W. Doehner [et al.]//Circulation -2002. -Vol.105 -P.2619.
Falasca, G.F. Superoxide anion production and phagocytosis of crystals by cultured endothelial cells./G.F. Falasca [et al.]//Arthritis Rheum. -1993. -Vol.36 -P. 105-116.
Faraci, F.M. Heistad D.D. Regulation of the cerebral circulation: role of endothelium and potassium channels./F.M. Faraci, D. D. Heistad//Physiol Rev -1998. -Vol.78(1) -P. 5397.
Fessel, F. J. High uric acid as an indicator of cardiovascular disease. Independence from obesity./F. J. Fessel//Am J Med -1980. -Vol.68 -P.401-404.
Gutman, A.B. Views on the pathgenesis and management of primary gout./A.B. Gutman//J. Bone Joint Surg. -1972. -Vol. 54A -P. 357-372.
Hopkins, P. Higher plasma homocysteine and increased susceptibility to adverse effects of low folate in early familial coronary artery disease./P. Hopkins [et al.]//Arterioscler Thromb Vasc Biol -1995. -Vol.15 -P. 1314-1320.
Istok, R. Total plasma homocysteine in patients with gout./R. Istok, M. Kovalancik, J. Rovensky//J. Rheumatol. -1999. -Vol. 26(9). -P. 2068-2069.
Janssens, H.J. Gout, just a nasty event or a cardiovascular signal? A study from primary care./H.J. Janssens [et al.]//Family Practice -2003. -Vol.20. -P.413-416.
Kato, M. Status of endothelial dependent vasodilation in patients with hyperuricemia./M. Kato, I. Hisatome, Y. Tomikura//Am J Cardiol. -2005. -Vol. 96(11). -P. 1576-1578.
Krishnan, E. Gout and the risk of acute myocardial infarction./E. Krishnan [et al.]//Arthritis Rheum. -2006. -Vol. 54 -P. 2688-2696.
Landgren, F. Plasma homocysteine in acute myocardial infarction: homocysteine-lowering effect of folic acid./F. Landgren//J Int Med -1995. -Vol.237 -P.381-388.
Lussier-Cacan, S. Plasma total homocysteine in healthy subjects: sex-specific relation with biological traits./S. Lussier-Cacan [et al.]//Am. J. Clin. Nutr. -1996. -Vol.64 -P.587-593.
Malinow, M.R. Role of blood pressure, uric acid, and hemorheological parameters on plasma homocysteine concentration./M. R. Malinow [et al.]//Atherosclerosis -1995. -Vol.114 -P. 175-183.
Marin, J. Role of vascular nitric oxide in physiological and pathological conditions./J. Marin, M. A. Rodriges-Martines//Pharmacol Ther -1997. -Vol.76 -P. 111-134.
Miguel, A. Roles of homocysteine in cell metabolism. Old and new functions./A. Miguel [et al.]//Eur. J. Biochem. -2001. -Vol.268 -P.3871-3882.
Moncada, S. Nitric oxide: physiology, pharmacology and pathophysiology./S. Moncada [et al.]//Pharmacol Rev -1991. -Vol.43 -P.109-142.
Panza, J.A. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependentvascular relaxation of patients with essential hypertension./J.A. Panza [et al.]//Circulation -1993. -Vol. 87.-P. 1468-1474.
Plasma homocysteine level and mortality in patients with coronary heart disease/O. Nygard [et al.]//N. Engl. J. Med. -1997. -Vol. 1337. -P. 230-236.
Schlotte, V. Effect of uric acid and chemical analogues on oxidation of human low density lipoprotein in vitro./V. Schlotte [et al.]//Free Rad Biol Med. -1998.-Vol.25. -P.839-847.
Skinner, K.A. Nitrosation of uric acid by peroxynitrite. Formation of a vasoactive nitric oxide donor./K.A. Skinner [et al.]//J Biol Chem. -1998. -Vol.273 -P. 24491-24497.
Tomita, M. Does hyperuricemia affect mortality? A prospective cohort study of Japanese male workers./M. Tomita [et al.]//J. Epidemiol -2000. -Vol.10. -P.403-409.
Tsutsumi, Z. Total plasma homocysteine is not increased in Japanese patients with gout./Z. Tsutsumi [et al.]//J Rheumatol. -2002. -Vol. 29(8) -P. 1805-1806.
Umans, J. G. Nitric oxide in the regulation of blood flow and arterial pressure/J. G. Umans, R. Levi//Ann Rev Physiol -1995. -Vol.57 -P. 771-790.
Van den Berg, M. Hyperhomocysteinaemia and endothelial dysfunction in young patients with peripheral arterial occlusive disease./M. Van den Berg [et al.]//Eur J Clin Invest -1995. -Vol.25 -P.176-181.
Webb, D.J. The pharmacology of human blood vessels in vivo./D.J. Webb//J Vasc Res. -1995. -Vol.32. -P.2-15.
Zhang, C. Homocysteine induces programmed cell death in human vascular endothelial cell throw activation of the unfoulded protein response/C. Zhang [et al.]//J. Biol. Chem. -2001. -Vol.276. -P. 35867-35874.
Zweier, J.L. Measurement of endothelial cell free radical generation: evidence for a central mechanism of free radical injury in postischemic tissues./J.L. Zweier [et al.]//Proc Natl Acad Sci USA. -1988. -Vol.85. -P. 4046-4050.
